David A Sallman

Trials

Studies that name David A Sallman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:51 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT04798339 · Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

  H. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Myelodysplastic Syndromes · principal investigator
• Ph1
  NCT04245397 · Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

  Syntrix Biosystems, Inc. · recruiting · Myelodysplastic Syndromes · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 05:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
  R44HL142389 · NHLBI · SYNTRIX BIOSYSTEMS, INC. · PI STUART J KAHN, DEAN YOSHIMASA MAEDA · fiscal years 2018 to 2020
  Named on NCT04245397
• A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
  R44CA291622 · NCI · SYNTRIX BIOSYSTEMS, INC. · PI Aaron D Schuler, JOHN A ZEBALA · fiscal years 2024 to 2026
  Named on NCT04245397